|
 |
 |
|
Medical Devices
and Diagnostics
Radical shifts are transforming how science understands
and treats disease; how health care players specialize, partner, and
compete. The traditional big pharma model is in decline, as the pipeline
for traditional small-molecule drugs slows. One result: a rise in high-growth
businesses based on medical devices, along with a convergence of treatments
administered by a combination of drugs and devices.
There used to be a world of difference between treating a patient with a device
- such as a hip replacement or a pacemaker - and using biology and biochemistry.
Different ailments required wholly different treatments, often with little
in common. But that is changing as medical advances foster combinations
of surgical implants and other hardware with support from medicines.
Drug-releasing stents were one of the first fruits of this trend, which
increasingly requires vastly different sorts of health-care firms to
mesh their research efforts.
Medical-device manufacturers will remain attractive acquisition targets especially for big pharma looking to hedge declines in their traditional businesses and the device industry should see continued consolidation while co-operating with biotech and pharmaceutical firms as they see fit.
Identifying market opportunities in the medical device sector in Asia has always been challenging, due largely to the lack of dependable market data and intelligence for companies to make informed investment decisions.
Clearstate specializes in providing medical device usage intelligence, along with in-depth market segmentation analysis services to help companies tap into this fast-growing healthcare sector.
|
|
|
|
